Forty Seven, Inc.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. 1.14%33.840.9%$1138.25m
JNJJohnson & Johnson 0.01%142.500.7%$1016.34m
BMYBristol-Myers Squibb Co. -1.17%57.431.0%$922.01m
MRKMerck & Co., Inc. 0.05%76.730.7%$787.68m
ABBVAbbVie, Inc. -1.18%96.781.9%$725.30m
LLYEli Lilly & Co. -1.84%163.391.1%$641.93m
AZNAstraZeneca Plc -0.40%53.761.2%$288.49m
RPRXRoyalty Pharma Plc -1.49%47.640.1%$203.76m
NVSNovartis AG -0.36%87.030.2%$143.34m
RGENRepligen Corp. -1.97%126.137.1%$115.34m
GSKGlaxoSmithKline Plc -1.14%39.910.2%$109.88m
NVONovo Nordisk A/S -0.26%65.440.1%$88.47m
RETAReata Pharmaceuticals, Inc. -1.10%154.403.4%$79.42m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -2.31%74.140.0%$67.56m
SNYSanofi -0.53%50.280.2%$63.74m

Company Profile

Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven's lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a ''don't eat me'' signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in six clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma and colorectal carcinoma.